Insulin Resistance Clinical Trial
— SLIM LIVEROfficial title:
A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Verified date | December 2022 |
Source | AIDS Clinical Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH, the use of semaglutide to reduce weight and the level of IHTG are experimental.
Status | Active, not recruiting |
Enrollment | 51 |
Est. completion date | August 30, 2023 |
Est. primary completion date | August 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Two separate reports of HIV-1 RNA measurements <50 copies/mL, and no HIV-1 RNA measurement >500 copies/mL, during the 48 weeks prior to entry. - No change in ART in 24 weeks prior to entry or plans to change during study. - Not meeting criteria for diabetes but with central adiposity (i.e., minimum waist circumference of =95 cm for individuals assigned male sex at birth or =94 cm for individuals assigned female sex at birth), =5% IHTG content, plus at least one of the following indicators of insulin resistance or pre-diabetes: fasting plasma glucose 100-125 mg/dL, HbA1c between 5.7% and <6.5%, or HOMA-IR >3.0. - Documented evidence of immunity to hepatitis A virus (HAV) or documented history of HAV vaccination within 30 days prior to entry. - CD4+ T-cell count =200 cells/mm3 within 30 days prior to pre-entry. - The following laboratory values obtained within 30 days prior to pre-entry: 1. Absolute neutrophil count (ANC) >750 cells/mm3. 2. Hemoglobin >10 g/dL for individuals assigned male sex at birth and >9 g/dL for individuals assigned female sex at birth. 3. Creatinine clearance (CrCl) =50 mL/min, as calculated by the CKD-Epi equation. 4. Aspartate aminotransferase (AST) (SGOT) =3 x ULN on at least two measures. 5. Alanine aminotransferase (ALT) (SGPT) =3 x ULN on at least two measures. 6. Fasting triglyceride level =500 mg/dL. - For individuals prescribed daily medications with anti-inflammatory properties, the doses must be stable. - For individuals taking daily lipid-lowering medications, the doses must be stable. - Agree to use contraception if able to become pregnant. - For individuals taking vitamin E (any dose), the dose must be stable. Exclusion Criteria: - Pregnant, breastfeeding, or plans to become pregnant. - Known active hepatitis C virus (HCV) infection. - Active/chronic hepatitis B virus (HBV). - Known retinopathy (excluding remote history of cotton wool spots). - Known active severe delayed gastric emptying. - Gain or loss of >5% body weight within 12 weeks prior to study entry. - Any plans to change diet or exercise regimen significantly, except for the adoption of study-provided suggestions for diet and exercise, within the study period. - Known acute or chronic liver disease with cirrhosis or portal hypertension. - History of liver transplant. - Current diagnosis of diabetes mellitus or current use of diabetes medications, or a laboratory measurement of hemoglobin A1c =6.5% at screening. - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). - History of unexplained hypercalcemia corrected for albumin that is >10.5 mg/dL. - Use of any immunomodulatory (including prednisone equivalent of =10 mg), HIV vaccine, investigational therapy, or TNF-a therapy within 3 months prior to study entry. - Use of human growth hormone, tesamorelin, supraphysiologic testosterone to achieve therapeutic blood levels, or any use of other anabolic steroids within 3 months prior to study entry or plans to start these while on study. - Use of estrogens or progesterones at supraphysiologic doses within 3 months prior to study entry. - Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation. - Current serious illness requiring systemic treatment and/or hospitalization. - Use of GLP-1 agonists within 24 weeks prior to study entry. - Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Excessive consumption of alcohol of =3 months within 90 days prior to screening. - Known chronic pancreatitis or more than one episode of pancreatitis ever in the past. - Intent to use any medication likely to cause significant changes in weight during the study period. - Use of stavudine within 12 months prior to study entry. - Prior bariatric surgery (e.g., lap band, gastric sleeve, or Roux-en-Y bypass surgery) or major gastric surgery or plans to undergo weight reduction surgery while on study. - Individuals with any metal, implantable devices (e.g., pacemakers, prosthetics), or shrapnel, per standard MRI exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
Brazil | 12101 Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS | Rio de Janeiro | |
United States | 6101 University of Colorado Hospital CRS | Aurora | Colorado |
United States | 201 Johns Hopkins University CRS | Baltimore | Maryland |
United States | 31788 Alabama CRS | Birmingham | Alabama |
United States | 101 Massachusetts General Hospital (MGH) CRS | Boston | Massachusetts |
United States | 2401 Cincinnati CRS | Cincinnati | Ohio |
United States | 31473 Houston AIDS Research Team (HART) CRS | Houston | Texas |
United States | 1401 University of Washington AIDS CRS | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
AIDS Clinical Trials Group | National Institute of Allergy and Infectious Diseases (NIAID) |
United States, Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change (absolute) in intra-hepatic triglyceride (IHTG) (%) | To evaluate whether 24 weeks of semaglutide will improve IHTG in ART-treated, adults with HIV, hepatic steatosis, central obesity, and insulin resistance or pre-diabetes. The primary comparison will examine the absolute change in IHTG from pre-entry to week 24. | From pre-entry to week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A | |
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 |